Cancer News and Research

Latest Cancer News and Research

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Researchers today published promising results for a drug that could lead to a replacement for the very effective but difficult-to-use blood thinner Coumadin (sold generically as Warfarin), currently taken by millions of Americans to reduce their risk of stroke.

31 Aug 2009

New director appointed at the Saint John’s Neuroscience Institute

Saint John’s Health Center today announced the appointment of world-renowned neurosurgeon Amin Kassam, MD, as Director of the new Saint John’s Neuroscience Institute and faculty member of the John Wayne Cancer Institute at Saint John’s. Dr. Kassam will lead the development of the new Neuroscience Institute which will offer an international minimally invasive neurosurgery center, as well as neuro-oncology, neuro-vascular surgery and other neuroscience services.

31 Aug 2009

Geron to present updates on product development programs at four investor conferences in September

Geron Corporation today announced that the company will present updates of its product development programs at four investor conferences in the month of September.

31 Aug 2009

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Peregrine Pharmaceuticals, Inc., today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program.

31 Aug 2009

Holistic health expert highlights the benefits of regular meditatation

Medical costs this year are hitting almost everyone in the pocketbook. With politicians scrambling to come up with a workable solution, Americans face dark days ahead as monthly insurance fees go up again, often with double-digit rate hikes. Is there any hope for hard-working Americans who face the challenge of paying these exorbitant fees?

31 Aug 2009

Doxorubicin granted orphan drug designation by the FDA

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath's request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.

31 Aug 2009

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy. The research is published online today in the journal Oncogene.

31 Aug 2009

Nuevolution partners with Novartis for drug research

Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Novartis.

31 Aug 2009

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. An initial study in patients conducted jointly by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital has found that the treatment has no unwanted side-effects.

31 Aug 2009

Cyberknife Robotic Radiosurgery System to be showcased at the ESTRO conference

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the company will showcase the treatment planning capabilities of the CyberKnife(R) Robotic Radiosurgery System at the 10th Biennial European Society for Therapeutic Radiology and Oncology (ESTRO) Conference on Physics and Radiation Technology for Clinical Radiotherapy in Maastricht, The Netherlands.

31 Aug 2009

Varian Medical Systems unveils first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities

Varian Medical Systems is introducing the world's first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities for international cancer clinics. Varian's UNIQUE(TM) radiotherapy system is expected to make advanced care more affordable and more widely available to cancer patients around the world.

31 Aug 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

Leading experts in health and health care reform to take part in symposium

With the nation facing a $9 trillion deficit over the next 10 years, according to government estimates, the future of health care reform depends upon a neglected but critical leg of the equation: cost. Some of the nation’s leading experts in health and health care reform will provide insights into this issue when they converge in Nashville Saturday for a nonpartisan public discussion.

29 Aug 2009

Cancer Immunotherapy Index of ten cancer immunotherapy stocks increases by 23%

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector.

29 Aug 2009

BioAlliance Pharma to discuss nanoparticle technology and its therapeutic applications at the French-Norwegian Interdisciplinary Symposium

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.

29 Aug 2009

New contract agreement reached between Stanford Hospital & Clinics, Packard Children’s hospital and the SEIU-UHW union

Lucile Packard Children’s Hospital and Stanford Hospital & Clinics announce that the hospitals have reached a new contract agreement with employees represented by the SEIU United Healthcare Workers West (SEIU-UHW) union. The SEIU-UHW membership, which represents 1,450 out of 9,172 employees at the hospitals in jobs such as housekeeping, food service, nursing assistants, and technicians, ratified the contract in a vote Thursday, August 27.

29 Aug 2009

Vision document to guide CHA's support to health reform

The Catholic Health Association of the United States (CHA) has long been committed to a goal of health coverage for all people in the United States. CHA has not, however, endorsed any of the bills currently under consideration.

29 Aug 2009

Research journal to host a webinar on apoptotic signalling in normal and cancer cell biology

The business office of Science, the world's leading peer-reviewed research journal, is producing a webinar on "Apoptotic Signaling in Normal and Cancer Cell Biology" to be broadcast live online at 12 noon ET (4:00 GMT) September 22, 2009, sponsored by Promega.

29 Aug 2009

Provident Healthcare Partners to provide strategic advisory services for NCIS' growth in oncology management field

New Century Infusion Solutions (NCIS), the first Integrated Single Specialty Provider (ISSP) focused on providing comprehensive management solutions to the oncology market, announced that it has retained Provident Healthcare Partners, a middle-market investment banking and advisory firm, to provide strategic advisory services in support of NCIS’s growth in the rapidly growing field of oncology management.

29 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Cancer News and Research

Latest Cancer News and Research

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

New director appointed at the Saint John’s Neuroscience Institute

Geron to present updates on product development programs at four investor conferences in September

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Holistic health expert highlights the benefits of regular meditatation

Doxorubicin granted orphan drug designation by the FDA

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

Nuevolution partners with Novartis for drug research

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

Cyberknife Robotic Radiosurgery System to be showcased at the ESTRO conference

Varian Medical Systems unveils first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Leading experts in health and health care reform to take part in symposium

Cancer Immunotherapy Index of ten cancer immunotherapy stocks increases by 23%

BioAlliance Pharma to discuss nanoparticle technology and its therapeutic applications at the French-Norwegian Interdisciplinary Symposium

New contract agreement reached between Stanford Hospital & Clinics, Packard Children’s hospital and the SEIU-UHW union

Vision document to guide CHA's support to health reform

Research journal to host a webinar on apoptotic signalling in normal and cancer cell biology

Provident Healthcare Partners to provide strategic advisory services for NCIS' growth in oncology management field

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in